Evaluation of WO2012177707 and WO2012097269: Vertex's phosphate prodrugs of gyrase and topoisomerase antibacterial agents

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 9, 2013, Pages 1233-1237

  Finn, John ^a  

^a Trius Therapeutics   (United States)

Author keywords

Antibacterial; DNA gyrase; Prodrugs; Topoisomerase IV

Indexed keywords

ANTIBIOTIC AGENT; BENZIMIDAZOLE DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG; WO 2012097269; WO 2012177707;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SCREENING; DRUG SOLUBILITY; HUMAN; KIDNEY INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATENT;

ANIMALS; ANTI-BACTERIAL AGENTS; BENZIMIDAZOLES; DNA GYRASE; DNA TOPOISOMERASE IV; GRAM-POSITIVE BACTERIA; HUMANS; PATENTS AS TOPIC; PHOSPHATES; PRODRUGS; SOLUBILITY; TOPOISOMERASE II INHIBITORS;

EID: 84882795259     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.820707     Document Type: Article

References (23)

1. Arias C, Murray B. Antibiotic-resistant bugs in the 21st century - a clinical super challenge. N Engl J Med 2009;360:439-43
2. Klein E, Smith D, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States 1999-2005. Emerg Infect Dis 2007;13:1840-6
3. Boucher H, Talbot G, Bradley J, et al. Bad bugs, no drugs: No ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis 2009;48:1-12
4. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011;24:71-109
5. Payne D, Gwynn M, Holmes D, et al. Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat Rev Drug Dis 2007;6:29-40
6. Collin F, Karkare S, Maxwell A. Exploiting bacterial DNA gyrase as a drug target: Current state and perspectives. Appl Microbiol Biotechnol 2011;92:479-97
7. Sissi C, Palumbo M. In front of and behind the replication fork: Bacterial type IIa topoisomerases. Cell Mol Life Sci 2010;67:2001-24
8. Lambert HP, O'Grady FW. editors. Coumarins. Churchill Livingstone; Edinburgh: 1992
9. Boehm H, Boehringer M, Bur D, et al. Novel inhibitors of DNA gyrase: 3D structure biased needle screening hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem 2000;43:2664-74
10. Lubbers T, Angehrn P, Gmunder H, et al. Design, synthesis and structure-Activity relationship studies of ATP analogs as DNA gyrase inhibitors. Bioorg Med Chem Lett 2000;10:821-6
11. Oblak M, Kotnik M, Solmajer T. Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr Med Chem 2007;14:2033-47
12. Vertex Pharmaceuticals.Gyrase. Inhibitors and Uses Thereof 2012. WO2002060879
13. Mani N, Gross C, Parsons J, et al. In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrob Agents Chemother 2006;50:1228-37
14. Grossman T, Bartels D, Mullin S, et al. Dual targeting of GyrB and ParE by a novel Aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother 2007;51:657-66
15. Charifson P, Grillot A, Grossman T, et al. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: Intelligent design and evolution through the judicious use of structure-guided design and structure-Activity relationships. J Med Chem 2008;51:5243-63
16. Silver L. Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Dis 2007;6:41-55
17. Vertex Pharmaceuticals. Pyrimidine gyrase and topoisomerase IV inhibitors 2012. WO2012097269
18. Vertex Pharmaceuticals. Phosphate esters of gyrase and topoisomerase inhibitors 2012. WO2012177707
19. Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: Design and clinical applications. Nat Rev Drug Dis 2008;7:255-70
20. Im WB, Choi SH, Park JY, et al. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur J Med Chem 2011;46:1027-39
21. Baker W, Cai S, Dimitroff M, et al. A prodrug approach toward the development of water soluble fluoroquinolones and structure-Activity relationships of quinoline-3-carboxylic acids. J Med Chem 2004;47:4693-709
22. Vertex Pharmaceuticals. Process for making gyrase and topoisomerase IV inhibitors 2012. WO2012097274
23. Vertex Pharmaceuticals. Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro- 5-[ 2-(1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl] -7-(tetrahydrofuran-2-yl)- 1H-benzimidazol-2-yl]urea 2012. WO2012097273